Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18658343 | UNIVERSAL DONOR STEM CELLS AND RELATED METHODS | May 2024 | August 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18658385 | UNIVERSAL DONOR STEM CELLS AND RELATED METHODS | May 2024 | February 2026 | Allow | 21 | 2 | 1 | Yes | No |
| 18434746 | EXPRESSION CASSETTE CONTAINING OVERLAPPING OPEN READING FRAMES AND APPLICATION | February 2024 | July 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18371839 | FUNCTIONAL FELINE PANCREATIC CELLS FROM ADIPOSE TISSUE | September 2023 | December 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 18472072 | UNIVERSAL DONOR CELLS AND RELATED METHODS | September 2023 | November 2025 | Allow | 26 | 1 | 0 | No | No |
| 18278100 | METHODS FOR CULTURING AND DIFFERENTIATING PLURIPOTENT CELLS INTO PROGENITOR OR MATURE MUSCLE CELLS AND COMPOSITION COMPRISING SAID CELLS | August 2023 | July 2025 | Allow | 23 | 2 | 1 | Yes | No |
| 18448674 | Methods and Culture Substrates for Controlled Induction of Biomimetic Neural Tissues Comprising Singular Rosette Structures | August 2023 | September 2025 | Allow | 25 | 1 | 0 | Yes | No |
| 18271677 | SIMULATION METHOD FOR CHRONIC ATROPHIC GASTRITIS (CAG) LESION AND IDENTIFICATION METHOD FOR MOUSE MODELING | July 2023 | May 2025 | Abandon | 22 | 2 | 0 | No | No |
| 18340537 | COMPOSITIONS AND METHODS FOR ORGANOID GENERATION AND DISEASE MODELING | June 2023 | November 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18210821 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | June 2023 | May 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18322105 | ACCELERATION OF STEM CELL DIFFERENTIATION | May 2023 | July 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18321400 | Chimeric Antigen Receptor | May 2023 | July 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18319677 | METHODS FOR EXPANDING AND ACTIVATING yo T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES | May 2023 | June 2025 | Allow | 25 | 1 | 0 | Yes | No |
| 18317465 | METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAS | May 2023 | January 2026 | Allow | 32 | 1 | 1 | No | No |
| 18128994 | COMPOSITIONS AND METHODS FOR MAMMALIAN GENETICS AND USES THEREOF | March 2023 | November 2025 | Allow | 32 | 1 | 1 | Yes | No |
| 18119405 | CANCER DETECTION METHOD USING SENSE OF SMELL OF NEMATODE | March 2023 | September 2025 | Allow | 30 | 1 | 1 | Yes | No |
| 18179814 | SIMULTANEOUS SPATIO-TEMPORAL MEASUREMENT OF GENE EXPRESSION AND CELLULAR ACTIVITY | March 2023 | October 2023 | Allow | 7 | 1 | 0 | No | No |
| 18115283 | Methods of Producing Specialized Cardio-Like Cells from Stem Cells | February 2023 | February 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18110276 | HUMANIZED LIGHT CHAIN MICE | February 2023 | June 2025 | Allow | 28 | 1 | 0 | No | No |
| 18166503 | HLA-F-MODIFIED CELLS AND METHODS | February 2023 | April 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 18106972 | Retroviral Vector | February 2023 | January 2025 | Allow | 23 | 4 | 1 | Yes | Yes |
| 18106039 | OPTIMIZED CRISPR-CAS DOUBLE NICKASE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | February 2023 | October 2025 | Allow | 32 | 2 | 0 | No | No |
| 18160825 | TARGETED REPLACEMENT OF ENDOGENOUS T CELL RECEPTORS | January 2023 | June 2025 | Allow | 29 | 1 | 0 | No | No |
| 18099852 | METHODS FOR MAKING INSULIN IN VIVO | January 2023 | June 2025 | Allow | 29 | 1 | 0 | Yes | No |
| 18016866 | EXPRESSION CASSETTE FOR EXPRESSING GENE COMPRISING OVERLAPPING OPEN READING FRAMES IN INSECT CELL AND APPLICATION THEREOF | January 2023 | August 2025 | Allow | 31 | 3 | 1 | Yes | No |
| 18151369 | UNIVERSAL DONOR CELLS | January 2023 | September 2025 | Allow | 32 | 1 | 1 | Yes | No |
| 18147554 | HEMATOPOIETIC STEM AND PROGENITOR CELLS DERIVED FROM HEMOGENIC ENDOTHELIAL CELLS BY EPISOMAL PLASMID GENE TRANSFER | December 2022 | July 2024 | Allow | 18 | 2 | 0 | Yes | No |
| 18083912 | CELLULAR MICROCOMPARTMENT AND PREPARATION PROCESSES | December 2022 | July 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 18062252 | COMPOSITION FOR INCREASING EXPRESSION OF BLOOD COAGULATION FACTOR GENE, COMPRISING CORE-SHELL STRUCTURED MICROPARTICLES AS ACTIVE INGREDIENT | December 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17993667 | UNIVERSAL DONOR STEM CELLS AND RELATED METHODS | November 2022 | March 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 17993659 | UNIVERSAL DONOR STEM CELLS AND RELATED METHODS | November 2022 | October 2024 | Allow | 23 | 1 | 1 | No | No |
| 17993674 | UNIVERSAL DONOR STEM CELLS AND RELATED METHODS | November 2022 | March 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 17993680 | UNIVERSAL DONOR STEM CELLS AND RELATED METHODS | November 2022 | March 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 17985746 | METHODS OF ENHANCING STEM CELL DIFFERENTIATION INTO BETA CELLS | November 2022 | February 2024 | Abandon | 15 | 2 | 0 | Yes | No |
| 18054860 | METHODS OF ENHANCING STEM CELL DIFFERENTIATION INTO BETA CELLS | November 2022 | January 2026 | Allow | 38 | 5 | 0 | Yes | Yes |
| 17969254 | GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH COMMON LIGHT CHAIN IMMUNOGLOBULIN LOCUS | October 2022 | March 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17968675 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | October 2022 | March 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17959203 | PANCREATIC CELLS FOR TREATING DIABETES AND METHODS OF GENERATING THE SAME | October 2022 | October 2025 | Abandon | 36 | 2 | 1 | No | No |
| 17944937 | TRANSGENIC ANIMAL PHENOTYPING PLATFORM AND USES THEREOF | September 2022 | July 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17818669 | UNIVERSAL DONOR CELLS | August 2022 | May 2025 | Allow | 33 | 1 | 1 | No | No |
| 17841117 | NUCLEIC ACID CONSTRUCTS ENCODING CHIMERIC NK RECEPTOR, CELLS CONTAINING, AND THERAPEUTIC USE THEREOF | June 2022 | August 2023 | Allow | 14 | 1 | 1 | Yes | No |
| 17832162 | METHODS | June 2022 | January 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 17832225 | Method for Depleting Malignant T-Cells | June 2022 | September 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17832371 | Method for Depleting Malignant T-Cells | June 2022 | September 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17832341 | METHODS | June 2022 | January 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 17830739 | METHODS FOR LOWERING BLOOD GLUCOSE | June 2022 | October 2025 | Allow | 41 | 2 | 0 | Yes | No |
| 17827142 | DETECTION OF A DEFECT ON HLA-E RESTRICTED CD8+ T REGULATORY CELLS | May 2022 | July 2023 | Allow | 14 | 2 | 1 | Yes | No |
| 17752505 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | May 2022 | February 2026 | Allow | 45 | 2 | 1 | Yes | No |
| 17749735 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO SINGLE HORMONAL INSULIN POSITIVE CELLS | May 2022 | September 2024 | Allow | 28 | 1 | 0 | No | No |
| 17748683 | CHIMERIC NK RECEPTOR AND METHODS FOR TREATING CANCER | May 2022 | March 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17728790 | Methods and Systems for Guide RNA Design and Use | April 2022 | May 2023 | Allow | 12 | 1 | 1 | Yes | No |
| 17725478 | TARGETED REPLACEMENT OF ENDOGENOUS T CELL RECEPTORS | April 2022 | November 2022 | Allow | 7 | 1 | 0 | No | No |
| 17724907 | METHOD FOR INDUCING ANTIGEN SPECIFIC CD8 POSITIVE T CELLS | April 2022 | April 2025 | Allow | 36 | 1 | 0 | No | No |
| 17769456 | GROWTH INHIBITOR | April 2022 | October 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17767524 | Epicardial Delivery of Gene Therapy | April 2022 | December 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17715889 | METHODS AND MATERIALS FOR HEMATOENDOTHELIAL DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS UNDER DEFINED CONDITIONS | April 2022 | December 2025 | Allow | 44 | 2 | 1 | No | No |
| 17706272 | COMPOSITIONS AND METHODS FOR ORGANOID GENERATION AND DISEASE MODELING | March 2022 | February 2023 | Allow | 10 | 1 | 1 | No | No |
| 17704429 | USE OF ENTPD3 FOR IDENTIFICATION, ISOLATION, AND ENHANCING MATURE STEM CELL DERIVED INSULIN-PRODUCING CELLS | March 2022 | December 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17685586 | DNA ANTIBODY CONSTRUCTS AND METHOD OF USING SAME | March 2022 | January 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17679128 | HLA-F-MODIFIED CELLS AND METHODS | February 2022 | September 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17671571 | DUAL STRAND NUCLEIC ACID-GUIDED NICKASE EDITING | February 2022 | June 2023 | Allow | 16 | 2 | 0 | No | No |
| 17579169 | REPROGRAMMING METHODS AND CELL CULTURE PLATFORMS | January 2022 | January 2026 | Allow | 47 | 2 | 1 | Yes | Yes |
| 17573552 | METHODS OF USING PDX1-POSITIVE PANCREATIC ENDODERM CELLS AND ENDOCRINE PRECURSOR CELLS | January 2022 | August 2024 | Allow | 31 | 2 | 0 | Yes | No |
| 17569896 | Methods and Compositions for Treatment of Disorders and Diseases Involving RDH12 | January 2022 | May 2025 | Allow | 40 | 7 | 0 | Yes | Yes |
| 17566924 | UNIVERSAL DONOR CELLS | December 2021 | October 2022 | Allow | 10 | 1 | 1 | Yes | No |
| 17559140 | RAAV WITH CHEMICALLY MODIFIED CAPSID | December 2021 | July 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17619614 | COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF | December 2021 | January 2026 | Allow | 49 | 1 | 1 | No | No |
| 17550945 | GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE | December 2021 | May 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17541818 | SIMULTANEOUS SPATIO-TEMPORAL MEASUREMENT OF GENE EXPRESSION AND CELLULAR ACTIVITY | December 2021 | February 2023 | Allow | 14 | 2 | 1 | Yes | No |
| 17532075 | A Lentivirus Packaging System Comprising a Synthetic Positive Feedback Loop | November 2021 | September 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17514609 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | October 2021 | December 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17499569 | COLONY FORMING MEDIUM AND USE THEREOF | October 2021 | October 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17497927 | UNIVERSAL DONOR STEM CELLS AND RELATED METHODS | October 2021 | June 2022 | Allow | 8 | 1 | 0 | No | No |
| 17489308 | PROTECTED GUIDE RNAS (PGRNAS) | September 2021 | October 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17474393 | METHODS, COMPOSITIONS AND SYSTEMS FOR PRODUCTION OF RECOMBINANT SPIDER SILK POLYPEPTIDES | September 2021 | June 2025 | Allow | 45 | 1 | 1 | No | No |
| 17472263 | STEM CELL DERIVED ISLET DIFFERENTIATION | September 2021 | September 2022 | Allow | 12 | 2 | 0 | Yes | No |
| 17468225 | T Cell Modification and Use Thereof | September 2021 | July 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17390673 | TARGETED REPLACEMENT OF ENDOGENOUS T CELL RECEPTORS | July 2021 | January 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17383760 | UNIVERSAL DONOR CELLS | July 2021 | July 2022 | Allow | 12 | 1 | 1 | Yes | No |
| 17375293 | METHODS FOR THE IN VITRO MANUFACTURE OF GASTRIC FUNDUS TISSUE AND COMPOSITIONS RELATED TO SAME | July 2021 | September 2025 | Abandon | 50 | 3 | 0 | No | No |
| 17375368 | ISOLATION AND CULTIVATION OF STEM/PROGENITOR CELLS FROM THE AMNIOTIC MEMBRANE OF UMBILICAL CORD AND USES OF CELLS DIFFERENTIATED THEREFROM | July 2021 | December 2024 | Abandon | 41 | 2 | 0 | No | No |
| 17369525 | GENE THERAPY FOR OCULAR DISORDERS | July 2021 | April 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17341220 | NUTRIENT MEDIA FOR THE PRODUCTION OF SLAUGHTER-FREE MEAT | June 2021 | February 2024 | Allow | 33 | 4 | 1 | Yes | No |
| 17306537 | COMPOSITIONS FOR THE MOBILIZATION, HOMING, EXPANSION AND DIFFERENTIATION OF STEM CELLS AND METHODS OF USING THE SAME | May 2021 | March 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17245405 | METHODS AND COMPOSITIONS FOR ASSESSING CRISPR/CAS-MEDIATED DISRUPTION OR EXCISION AND CRISPR/CAS-INDUCED RECOMBINATION WITH AN EXOGENOUS DONOR NUCLEIC ACID IN VIVO | April 2021 | March 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17242937 | METHODS OF CANCER IMMUNOTHERAPY | April 2021 | October 2025 | Abandon | 54 | 3 | 1 | No | No |
| 17241947 | CANCER DETECTION METHOD USING SENSE OF SMELL OF NEMATODE | April 2021 | March 2026 | Allow | 59 | 4 | 1 | Yes | No |
| 17241032 | ADENO-ASSOCIATED VARIANTS, FORMULATIONS AND METHODS FOR PULMONARY DELIVERY | April 2021 | September 2022 | Allow | 17 | 3 | 0 | Yes | No |
| 17288442 | New Tools for Improving Gene Therapy and Use Thereof | April 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17230354 | Compositions and Methods for Correction of Heritable Ocular Disease | April 2021 | November 2025 | Allow | 55 | 1 | 1 | Yes | No |
| 17200301 | TARGETED REPLACEMENT OF ENDOGENOUS T CELL RECEPTORS | March 2021 | May 2021 | Allow | 2 | 0 | 0 | Yes | No |
| 17172581 | RAAV WITH CHEMICALLY MODIFIED CAPSID | February 2021 | November 2021 | Allow | 9 | 1 | 1 | Yes | No |
| 17168774 | METHODS FOR EXPRESSING PROTEINS IN AXONS | February 2021 | January 2024 | Allow | 35 | 1 | 0 | No | No |
| 17160087 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO PANCREATIC ENDOCRINE CELLS USING HB9 REGULATORS | January 2021 | May 2024 | Abandon | 39 | 1 | 1 | No | No |
| 16958630 | ANTIBODY-MODIFIED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL AND USES THEREOF | January 2021 | March 2025 | Allow | 57 | 1 | 1 | Yes | No |
| 17148556 | UNIVERSAL DONOR STEM CELLS AND RELATED METHODS | January 2021 | October 2022 | Allow | 21 | 2 | 1 | Yes | No |
| 17148425 | GENOME-MODIFIED RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS | January 2021 | July 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17141327 | COMPOSITIONS AND METHODS FOR TREATING TYPE 1 AND TYPE 2 DIABETES AND RELATED DISORDERS | January 2021 | September 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 17253956 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MUSCLE SPECIFIC MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY | December 2020 | March 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17124667 | A method of cell therapy | December 2020 | January 2025 | Allow | 49 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MONTANARI, DAVID A.
With a 46.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 29.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MONTANARI, DAVID A works in Art Unit 1632 and has examined 845 patent applications in our dataset. With an allowance rate of 58.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner MONTANARI, DAVID A's allowance rate of 58.1% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MONTANARI, DAVID A receive 2.44 office actions before reaching final disposition. This places the examiner in the 71% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by MONTANARI, DAVID A is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +52.5% benefit to allowance rate for applications examined by MONTANARI, DAVID A. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.7% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 37.2% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 46.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 41% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 84.9% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 80.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 74.1% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 9.3% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 54% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.